Health Care

Centene’s stock trades near its 52‑week low, yet its vast Medicaid/Medicare network offers a stable base—watch policy shifts and earnings for upside.

Discover how Novo Nordisk’s partnership with Abbott India and FDA approval of Sogroya broaden its diabetes, obesity and pediatric therapy reach—boosting global market growth.

Cooper Cos Inc‑The: resilient eye‑care stock showing 8 % revenue growth, AI‑diagnostic pipeline, and strong balance sheet amid regulatory and tariff risks.

Explore Natera Inc.’s 2025 earnings and breakthrough Signatera MRD platform—showing 18% revenue growth, 42% gross margin, and clinical data that could shape personalized cancer treatment and reimbursement approvals.

Amgen’s stock rebounds as analyst upgrades and a robust therapy pipeline—including CAR‑T and kinase inhibitors—boost investor confidence and signal strong growth prospects.

Genmab A/S boosts governance by issuing RSUs and warrants, aligning executives with shareholder value while meeting market‑abuse rules – a transparent move that may drive long‑term growth.

WuXi AppTec’s strong CDMO performance, rising investor confidence, and China’s value‑based reimbursement push the biotech firm ahead of global peers—why it’s a top pick for biotech investors.

Grifols SA’s 2025 results show robust profit growth and debt cut, with a 2026 outlook targeting 25 % operating profit rise driven by new plasma‑derived therapies and regulatory approvals.

Solventum Corp beats Q4 2025 earnings, driven by high‑margin SurgiSeal and SterilPro sales; analysts see modest 2‑3 % 2026 growth, margin gains, and new AI‑enabled sterilisation tech boosting patient safety and operational efficiency.

Gilead’s Phase 3 ARTISTRY results show a single‑tablet bictegravir/lenacapavir combo keeping HIV suppressed, positioning it for long‑acting therapy, market access, and strategic growth.